Focus: Gedeon Richter is a 120+ year-old Hungarian pharmaceutical company with 1,001-5,000 employees, focused on small molecules and generics across neurology, cardiovascular, metabolic, and immunology markets.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Gedeon Richter to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Post-loss-of-exclusivity product generating commoditized revenue with limited differentiation or growth potential.
Help build intelligence for Gedeon Richter
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Gedeon Richter's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Major cardiovascular generic in pre-launch phase, representing near-term commercial opportunity in large, competitive market.
Established antifungal generic with broad penetration in pre-launch portfolio, offering steady revenue in commodity segment.
Pre-launch antifungal generic entering competitive market with limited differentiation or premium positioning.
Richter Gedeon Nyrt. stock (HU0000123096): shares steady as Budapest pharma name digests recent divi - AD HOC NEWS
Richter Gedeon Nyrt. stock (HU0000123096): shares steady as Budapest pharma name digests recent divi AD HOC NEWS
Richter Gedeon stock (HU0000123096): Drugmaker updates investors after recent company news - AD HOC NEWS
Richter Gedeon stock (HU0000123096): Drugmaker updates investors after recent company news AD HOC NEWS
Richter Expands Rheumatology Portfolio with EU-Approved Medicine - Hungary Today
Richter Expands Rheumatology Portfolio with EU-Approved Medicine Hungary Today
Richter Gedeon Nyrt. Stock (HU0000123096): Upcoming Dividend Ex-Date Set for June 3, 2026 - AD HOC NEWS
Richter Gedeon Nyrt. Stock (HU0000123096): Upcoming Dividend Ex-Date Set for June 3, 2026 AD HOC NEWS
Applications Open for the 2026 Semmelweis–Richter Journalism Award - Semmelweis Egyetem
Applications Open for the 2026 Semmelweis–Richter Journalism Award Semmelweis Egyetem
Richter Expands Gynecology Portfolio with Major U.S. Acquisition - Hungary Today
Richter Expands Gynecology Portfolio with Major U.S. Acquisition Hungary Today
Showing 6 of 7 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women - Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study.
Life Engagement Improvements with Cariprazine in Schizophrenia: A Post-Hoc Analysis of PANSS Data from Short-Term Studies.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo